Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XRx 221

Drug Profile

XRx 221

Alternative Names: Xrx-221; XRx221

Latest Information Update: 28 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XORTX Pharma
  • Developer XORTX Therapeutics
  • Class Uroprotectives
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Diabetic nephropathies

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for phase-I development in Diabetic-nephropathies in Canada
  • 06 Apr 2021 XORTX Pharma has patent protection for the use of uric acid lowering agents to treat chronic progressing kidney disease, hypertension, insulin resistance, and diabetic nephropathy, in USA and Europe Union
  • 06 Apr 2021 XORTX Pharma receives notification of intent to grant a patent covering the use of uric acid lowering agents to treat and prevent diabetic nephropathies, in European Union
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top